A Phase 3 interventional study of ezetimibe with simvastatin and simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-02-08.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 33rd largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 50 in phase 3, and was the 7th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 14 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 45th largest by enrollment of the 81 interventional ones that give a count, is one of 17 that started in 2005, is one of 58 in phase 3, and was the 19th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, controlled, parallel-group, multicenter, Phase-3 study to evaluate the efficacy and safety of ezetimibe with simvastatin taken alone in subjects ages 10-17 years with Heterozygous Familial Hypercholesterolemia.
This study consisted of 3 distinct periods. In Period 1, subjects received daily treatment for 6 weeks as part of either the ezetimibe with simvastatin group or part of the simvastatin monotherapy group. Subjects in the ezetimibe with simvastatin group received one of three treatments: coadministration of ezetimibe 10 mg/day plus simvastatin 10 mg/day, 20 mg/day, or 40 mg/day. Subjects in the simvastatin monotherapy group received one of three treatments: ezetimibe placebo plus simvastatin 10 mg/day, 20 mg/day, or 40 mg/day. The primary and key secondary efficacy analysis were based on the evaluations performed during Period 1 and were presented as data for subjects pooled from either the ezetimibe with simvastatin treatment groups compared with data for subjects pooled from the simvastatin monotherapy treatment groups.
In Period 2, subjects received ezetimibe 10 mg/day plus simvastatin 40 mg/day or ezetimibe placebo plus simvastatin 40 mg/day for 27 additional weeks maintaining the same treatment assignment (coadministration vs monotherapy) as in Period 1.
In Period 3, all subjects received ezetimibe 10 mg/day plus open-label simvastatin daily for 20 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
Drug: ezetimibe with simvastatin
Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
Drug: simvastatin
Drug pages: Ezetimibe · Simvastatin
Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Least squares mean percent change from Baseline in LDL-C at the end of Step 1 (Week 6) in the pooled groups who received ezetimibe plus simvastatin compared with pooled groups who received simvastatin monotherapy
Time frame: baseline to 6 weeks
Percent Change From Baseline in Total Cholesterol (TC)
Time frame: baseline to 6 weeks
Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)
Time frame: baseline to 6 weeks
Percent Change From Baseline in Triglycerides (TG)
Time frame: baseline to 6 weeks
Percent Change From Baseline in Apolipoprotein B (Apo B)
Time frame: baseline to 6 weeks
Percent Change From Baseline in HDL-C
Time frame: baseline to 6 weeks
| Milestone | Ezetimibe/Simvastatin 10/10 | Ezetimibe/Simvastatin 10/20 | Ezetimibe/Simvastatin 10/40 | Ezetimibe Matching Placebo/ Simvastatin 10 | Ezetimibe Matching Placebo/ Simvastatin 20 | Ezetimibe Matching Placebo/ Simvastatin 40 | Long-term Experience Ezetimbe/Simvastatin |
|---|---|---|---|---|---|---|---|
| Started | 43 | 40 | 43 | 40 | 40 | 42 | 0 |
| Completed | 43 | 39 | 41 | 39 | 39 | 40 | 0 |
| Not completed | 0 | 1 | 2 | 1 | 1 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Milestone | Ezetimibe/Simvastatin 10/10 | Ezetimibe/Simvastatin 10/20 | Ezetimibe/Simvastatin 10/40 | Ezetimibe Matching Placebo/ Simvastatin 10 | Ezetimibe Matching Placebo/ Simvastatin 20 | Ezetimibe Matching Placebo/ Simvastatin 40 | Long-term Experience Ezetimbe/Simvastatin |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 122 | 0 | 0 | 118 | 0 |
| Completed | 0 | 0 | 114 | 0 | 0 | 113 | 0 |
| Not completed | 0 | 0 | 8 | 0 | 0 | 5 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Laboratory adverse event | 0 | 0 | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Milestone | Ezetimibe/Simvastatin 10/10 | Ezetimibe/Simvastatin 10/20 | Ezetimibe/Simvastatin 10/40 | Ezetimibe Matching Placebo/ Simvastatin 10 | Ezetimibe Matching Placebo/ Simvastatin 20 | Ezetimibe Matching Placebo/ Simvastatin 40 | Long-term Experience Ezetimbe/Simvastatin |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 228 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 222 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Subject moved | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Least squares mean percent change from Baseline in LDL-C at the end of Step 1 (Week 6) in the pooled groups who received ezetimibe plus simvastatin compared with pooled groups who received simvastatin monotherapy
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) | -49.45 ± 1.19 | -34.43 ± 1.22 |
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) | -38.23 ± .96 | -26.28 ± .99 |
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C) | -46.84 ± 1.13 | -32.68 ± 1.16 |
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) | -16.56 ± 30.26 | -12.28 ± 31.49 |
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) | -38.92 ± 1.1 | -26.69 ± 1.11 |
| percent change | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy |
|---|---|---|
| Percent Change From Baseline in HDL-C | 6.58 ± 1.16 | 6.47 ± 1.19 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe With Simvastatin | — | 4/126 (3.2%) | 58/126 (46%) |
| Simvastatin Monotherapy | — | 1/122 (0.8%) | 59/122 (48.4%) |
| Long-term Coadministration of Ezetimibe With Simvastatin | — | 3/227 (1.3%) | 42/227 (18.5%) |
| Event | Ezetimibe With Simvastatin | Simvastatin Monotherapy | Long-term Coadministration of Ezetimibe With Simvastatin |
|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 0/126 | 1/122 | 0/227 |
| PyrexiaGeneral disorders | 1/126 | 0/122 | 0/227 |
| Arthritis bacterialInfections and infestations | 1/126 | 0/122 | 0/227 |
| TonsillitisInfections and infestations | 1/126 | 0/122 | 0/227 |
| TendonitisMusculoskeletal and connective tissue disorders | 1/126 | 0/122 | 0/227 |
| EncephalopathyNervous system disorders | 1/126 | 0/122 | 0/227 |
| Pilonidal cystInfections and infestations | 0/126 | 0/122 | 1/227 |
| Subcutaneous abscessInfections and infestations | 0/126 | 0/122 | 1/227 |
| OverdoseInjury, poisoning and procedural complications | 0/126 | 0/122 | 1/227 |
| Event | Ezetimibe With Simvastatin | Simvastatin Monotherapy | Long-term Coadministration of Ezetimibe With Simvastatin |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 27/126 | 27/122 | 16/227 |
| HeadacheNervous system disorders | 16/126 | 16/122 | 6/227 |
| InfluenzaInfections and infestations | 8/126 | 12/122 | 12/227 |
| AcneSkin and subcutaneous tissue disorders | 4/126 | 9/122 | 3/227 |
| DiarrhoeaGastrointestinal disorders | 9/126 | 3/122 | 2/227 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/126 | 8/122 | 5/227 |
| NauseaGastrointestinal disorders | 8/126 | 4/122 | 2/227 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/126 | 1/122 | 0/227 |
| Age, Continuous(years) | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy | Total |
|---|---|---|---|
| Mean | 14.0 ± 1.9 | 14.3 ± 1.8 | 14.2 ± 1.9 |
| Sex: Female, Male(Participants) | Pooled Subjects Who Received Ezetimibe With Simvastatin | Pooled Subjects Who Received Simvastatin Monotherapy | Total |
|---|---|---|---|
| Female | 53 | 53 | 106 |
| Male | 73 | 69 | 142 |
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin